Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 51 69

Summaries for Hypoxia

Novus Biologicals : 53 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to cerebral hypoxia and polycythemia due to hypoxia, and has symptoms including anoxemia, cachexia and cheyne-stokes respiration. An important gene associated with Hypoxia is HIF1A (Hypoxia Inducible Factor 1 Alpha Subunit), and among its related pathways/superpathways are Development HGF signaling pathway and Pathways in cancer. The drugs Bosentan and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and brain, and related phenotypes are cardiovascular system and cellular

NINDS : 51 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)
id Related Disease Score Top Affiliating Genes
1 cerebral hypoxia 12.3
2 polycythemia due to hypoxia 11.8
3 anoxia 11.4
4 pulmonary edema 11.0
5 brain ischemia 11.0
6 apnea of prematurity 11.0
7 methemoglobinemia 11.0
8 dementia 11.0
9 tempi syndrome 11.0
10 methemoglobinemia, type i 10.8
11 asphyxia neonatorum 10.8
12 neonatal hypoxic and ischemic brain injury 10.8
13 isolated delta-storage pool disease 10.7 EGLN1 EPAS1
14 renal cell carcinoma 10.7
15 exudative vitreoretinopathy 5 10.7
16 exudative vitreoretinopathy 6 10.7
17 exudative vitreoretinopathy 4 10.7
18 exudative vitreoretinopathy 1 10.7
19 chronic mountain sickness 10.7
20 pneumothorax, primary spontaneous 10.7
21 methemoglobinemia, type iv 10.7
22 exudative vitreoretinopathy 2, x-linked 10.7
23 hantavirus pulmonary syndrome 10.7
24 severe acute respiratory syndrome 10.7
25 congenital laryngeal palsy 10.7
26 endotheliitis 10.7
27 atrioventricular septal defect 2 10.5 EGLN1 EPAS1 HIF1A VHL
28 central nervous system vasculitis 10.5 EPAS1 HIF1A VHL
29 cerebritis 10.5
30 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 EGLN1 HIF1A HIF1AN VHL
31 afferent loop syndrome 10.5 EGLN1 EPAS1 HIF1A VHL
32 cleft lip palate dysmorphism kumar type 10.5 EPAS1 HIF1A VHL
33 ischemia 10.5
34 breast cancer 10.4
35 gata1-related x-linked cytopenia 10.3 HIF1A VHL
36 polycystic kidney disease 10.3
37 neuronitis 10.3
38 mucinous tubular and spindle renal cell carcinoma 10.3 HIF1A MTOR VHL
39 prostatitis 10.3
40 pancreatitis 10.3
41 lung cancer 10.2
42 prostate cancer 10.2
43 squamous cell carcinoma 10.2
44 hepatocellular carcinoma 10.2
45 pancreatic cancer 10.2
46 glioma 10.2
47 glioblastoma 10.2
48 retinitis 10.2
49 adenocarcinoma 10.2
50 pulmonary hypertension 10.2

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


anoxemia, cachexia, cheyne-stokes respiration, coughing, cyanosis, dyspnea, edema, fever, headache, hemoptysis, hoarseness, icterus, seizures, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, syncope, vertigo, chills, reduced consciousness/confusion, hyperoxia, motor symptom, skin symptoms, hot flushes, physical symptom, increased sweating, physical appearance, body

MGI Mouse Phenotypes related to Hypoxia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 EGLN1 ARNT CITED2 EGLN2 EGLN3 HIF1A
2 cellular MP:0005384 10.39 EGLN1 ARNT CITED2 EGLN2 EGLN3 HIF1A
3 homeostasis/metabolism MP:0005376 10.38 EGLN1 ARNT CITED2 EGLN2 EGLN3 HIF1A
4 growth/size/body region MP:0005378 10.32 ARNT EGLN1 EGLN2 CITED2 EPAS1 EGLN3
5 hematopoietic system MP:0005397 10.27 ARNT EGLN1 EGLN2 CITED2 EPAS1 EGLN3
6 embryo MP:0005380 10.26 EGLN1 ARNT CITED2 EGLN2 EGLN3 HIF1A
7 immune system MP:0005387 10.23 ARNT EGLN1 EGLN2 CITED2 EPAS1 EGLN3
8 mortality/aging MP:0010768 10.22 ARNT EGLN1 CITED2 EPAS1 EGLN3 HIF1A
9 craniofacial MP:0005382 10.19 EGLN1 ARNT CITED2 EGLN2 EGLN3 HIF1A
10 muscle MP:0005369 10.18 EGLN2 EGLN3 EGLN1 HIF1A EP300 HIF1AN
11 nervous system MP:0003631 10.06 ARNT EGLN1 CITED2 EPAS1 EGLN3 HIF1A
12 liver/biliary system MP:0005370 10.03 ARNT EGLN1 EGLN2 EPAS1 EGLN3 HIF1A
13 normal MP:0002873 9.86 ARNT CITED2 EGLN3 HIF1A EP300 HIF1AN
14 renal/urinary system MP:0005367 9.81 EGLN1 ARNT CITED2 HIF1A EP300 P4HTM
15 respiratory system MP:0005388 9.61 EGLN1 CITED2 HIF1A EP300 EPAS1 HIF3A
16 vision/eye MP:0005391 9.23 CITED2 EPAS1 EGLN3 HIF1A EP300 P4HTM

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 1 147536-97-8 104865
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 437-38-7 3345
3
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3 2078-54-8 4943
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
6
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
7 Racepinephrine Approved Phase 4,Phase 2,Phase 3
8
Bromhexine Approved Phase 4 3572-43-8
9
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
10
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
11
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
12
Levodopa Approved Phase 4 59-92-7 6047
13
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
14
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
15
Succinylcholine Approved Phase 4 306-40-1 5314
16
Budesonide Approved Phase 4,Phase 1 51333-22-3 63006 5281004
17
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
18
Terbutaline Approved Phase 4 23031-25-6 5403
19
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2 59467-70-8 4192
20
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2 58-61-7 60961
21
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
22
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7487-88-9 24083
23
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
24
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2 10102-43-9 145068
25
Acetylcysteine Approved, Investigational Phase 4,Early Phase 1 616-91-1 12035
26
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
27
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
28
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
29
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
30
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
31
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
32
Bisoprolol Approved Phase 4 66722-44-9 2405
33
Doxapram Approved, Vet_approved Phase 4 309-29-5 3156
34
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
35
Etomidate Approved Phase 4 33125-97-2 36339 667484
36
Meperidine Approved Phase 4,Phase 2 57-42-1 4058
37
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
38
Nicorandil Approved Phase 4 65141-46-0 47528
39
Captopril Approved Phase 4 62571-86-2 44093
40
Ranibizumab Approved Phase 4 347396-82-1 459903
41
Dipyridamole Approved Phase 4 58-32-2 3108
42
Lorazepam Approved Phase 4 846-49-1 3958
43
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3 37350-58-6, 51384-51-1 4171
44
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
45
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
46
Cetirizine Approved Phase 4 83881-51-0 2678
47
Fexofenadine Approved Phase 4 83799-24-0 3348
48
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
49
Remifentanil Approved Phase 4 132875-61-7 60815
50
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263

Interventional clinical trials:

(show top 50) (show all 1195)

id Name Status NCT ID Phase Drugs
1 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
2 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
3 Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4 continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4 oxygen
6 Home Oxygen Therapy in Bronchiolitis Unknown status NCT01216553 Phase 4
7 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
8 CPAP in Liver Transplant Unknown status NCT00510770 Phase 4
9 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
10 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
11 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
12 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
13 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
14 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
15 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
16 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
17 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4 Lipo-PGE1
18 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
19 Muscle Fatigue and Carbonic Anhydrase Inhibitors Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
20 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
21 Ambulatory Oxygen Effects on Muscles in COPD Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
22 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4 Vitamin E, Vitamin C
23 Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Completed NCT02171910 Phase 4 Doxapram;Placebo
24 CPAP in SAHS Patients With Hypertension Completed NCT02398032 Phase 4
25 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
26 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
27 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4 Fentanyl;Fentanyl
28 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
29 Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Completed NCT01260662 Phase 4 Propofol;1:1 Propofol/Ketamine;4:1 Propofol/Ketamine
30 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
31 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
32 The Use of Statins for Myocardial Death Prevention Completed NCT00772564 Phase 4 Atorvastatin
33 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study) Completed NCT01103336 Phase 4 pretreatment with intravenous nicorandil vs. placebo before coronary angiography
34 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
35 Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition Completed NCT01545479 Phase 4 captopril 25mg
36 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea and Healthy Controls. Completed NCT00291993 Phase 4
37 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
38 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4 Dipyridamole;Placebo
39 Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation. Completed NCT02593448 Phase 4
40 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
41 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
42 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
43 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients Completed NCT01996124 Phase 4 Indacaterol Fumarate;Placebo
44 Bispectral Index and Clinical Parameters Evaluation in Dental Procedures Completed NCT02671578 Phase 4 Nitrous Oxide
45 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
46 Short Term Physiological Effects of Nasal High Flow Oxygen on Respiratory Mechanics Completed NCT02363920 Phase 4
47 Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Completed NCT00637455 Phase 4 fexofenadine HCl
48 Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy Completed NCT02602743 Phase 4 Remifentanyl;Propofol;Ketamine
49 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
50 Optiflow® to Prevent Post-Extubation Hypoxemia afteR Abdominal Surgery (the OPERA Trial) Completed NCT01887015 Phase 4

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

39
Endothelial, Lung, Brain, Prostate, Heart, Kidney, Liver

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 6598)
id Title Authors Year
1
FGF11 induced by hypoxia interacts with HIF-1I+ and enhances its stability. ( 28027390 )
2017
2
CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in hypoxia- versus normoxia-microenviroment. ( 28948499 )
2017
3
Macrophages Regulate Unilateral Ureteral Obstruction-Induced Renal Lymphangiogenesis through C-C Motif Chemokine Receptor 2-Dependent Phosphatidylinositol 3-Kinase-AKT-Mechanistic Target ofA Rapamycin Signaling and Hypoxia-Inducible Factor-1I+/Vascular Endothelial Growth Factor-C Expression. ( 28627412 )
2017
4
The Effect of Velvet Antler Proteins on Cardiac Microvascular Endothelial Cells Challenged with Ischemia-Hypoxia. ( 28936174 )
2017
5
Down-Regulation of EPAS1 Transcription and Genetic Adaptation of Tibetans to High-Altitude Hypoxia. ( 28096303 )
2017
6
Expression of hypoxia inducible factor 1 alpha and its clinical significance in esophageal carcinoma: A meta-analysis. ( 28671053 )
2017
7
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. ( 27913861 )
2017
8
Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia. ( 28952138 )
2017
9
Correction for Gabai et al., "Heat Shock Transcription Factor Hsf1 Is Involved in Tumor Progression via Regulation of Hypoxia-Inducible Factor 1 and RNA-Binding Protein HuR". ( 28951485 )
2017
10
Pulmonary Neuroendocrine Cell Hyperplasia in Hemoglobin Bart-induced Hydrops Fetalis: A model for Chronic Intrauterine Hypoxia. ( 28727978 )
2017
11
An Efficient and Reliable Assay for Investigating the Effects of Hypoxia/Anoxia on Drosophila. ( 28866769 )
2017
12
Elevated concentrations of hypoxia-inducible factor-1I+ in patients with fracture and concomitant traumatic brain injury. ( 27687082 )
2017
13
The role of SUMOylation in cerebral hypoxia and ischemia. ( 28323006 )
2017
14
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. ( 28939754 )
2017
15
Correction: Intermittent Hypoxia Effect on Osteoclastogenesis Stimulated by Neuroblastoma Cells. ( 28085942 )
2017
16
Protective effects of bellidifolin in hypoxia-induced in pheochromocytoma cells (PC12) and underlying mechanisms. ( 28895799 )
2017
17
Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. ( 28088075 )
2017
18
Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension. ( 28409279 )
2017
19
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. ( 28423608 )
2017
20
MicroRNA-433 Inhibits the Proliferation and Migration of HUVECs and Neurons by Targeting Hypoxia-Inducible Factor 1 Alpha. ( 27815672 )
2017
21
Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT. ( 28198519 )
2017
22
Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1I+ protein stability. ( 28279976 )
2017
23
Hypoxia inducible factor as a therapeutic target for atherosclerosis. ( 28942242 )
2017
24
Protective role of hypoxia-inducible factor-1I+-dependent CD39 and CD73 in fulminant acute liver failure. ( 27899277 )
2017
25
Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells. ( 27823907 )
2017
26
Hypoxia and extra-cellular matrix gene expression in adipose tissue associates with reduced insulin sensitivity in black South African women. ( 27628582 )
2017
27
Novel lnc RNA regulated by HIF-1 inhibits apoptotic cell death in the renal tubular epithelial cells under hypoxia. ( 28420760 )
2017
28
Hypoxia inducible factor-1I+-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease. ( 27921309 )
2017
29
Leptin acts on neoplastic behavior and expression levels of genes related to hypoxia, angiogenesis, and invasiveness in oral squamous cell carcinoma. ( 28459203 )
2017
30
The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors. ( 28944496 )
2017
31
Analysis of hypoxia-induced noncoding RNAs reveals metastasis-associated lung adenocarcinoma transcript 1 as an important regulator of vascular smooth muscle cell proliferation. ( 28056547 )
2017
32
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. ( 28046107 )
2017
33
Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis. ( 28886531 )
2017
34
Chronic Intermittent Hypoxia Differentially Impacts Different States of Inspiratory Activity at the Level of the preBAPtzinger Complex. ( 28936176 )
2017
35
Delayed Effects of Neonatal Administration of Non-Opioid Analog of Leu-Enkephalin on Cerebral Consequences of Antenal Hypoxia. ( 28948549 )
2017
36
Hypoxia and the hypoxia-regulated transcription factor HIF-1I+ suppress the host defence of airway epithelial cells. ( 28409544 )
2017
37
Sirtuin 6 suppresses hypoxia-induced inflammatory response in human osteoblasts via inhibition of reactive oxygen species production and glycolysis-A therapeutic implication in inflammatory bone resorption. ( 27534902 )
2017
38
Activation of hypoxia-inducible factor-1I+ by prolonged inA vivo hyperinsulinemia treatment potentiates cancerous progression in estrogen receptor-positive breast cancer cells. ( 28351619 )
2017
39
Loss of smooth muscle cell hypoxia inducible factor-1I+ underlies increased vascular contractility in pulmonary hypertension. ( 27811062 )
2017
40
Differential expression of thioredoxin binding protein-2/Txnip in human placenta: Possible involvement of hypoxia in its suppression during early pregnancy. ( 27762463 )
2017
41
Immunoexpression of GADD45I^ in the myocardium of newborns experiencing perinatal hypoxia. ( 28214215 )
2017
42
Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast-like phenotype via the TGF-I^1/Smad3 pathway. ( 27909731 )
2017
43
Hypoxia inducible factors regulate the transcription of the sprouty2 gene and expression of the sprouty2 protein. ( 28196140 )
2017
44
Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals. ( 28459376 )
2017
45
Administration of Huperzia quadrifariata Extract, a Cholinesterase Inhibitory Alkaloid Mixture, has Neuroprotective Effects in a Rat Model of Cerebral Hypoxia-Ischemia. ( 27885575 )
2017
46
Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1I+ and PERK signaling activation. ( 27785700 )
2017
47
Selective tubular activation of hypoxia-inducible factor-2I+ has dual effects on renal fibrosis. ( 28900259 )
2017
48
Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia. ( 28592433 )
2017
49
Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells. ( 28065858 )
2017
50
Correction for Ferrari et al., Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome. ( 28584118 )
2017

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
2 12.62 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
3 12.28 ARNT EGLN1 EPAS1 HIF1A HIF1AN HIPK2
4
Show member pathways
12.12 EP300 HIF1A HIPK2 PSMA7
5
Show member pathways
12.09 EP300 HIF1A HIPK2 RORA
6 11.85 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
7 11.83 EP300 HIF1A MTOR
8 11.81 ARNT EGLN1 EP300 HIF1A HIF1AN
9
Show member pathways
11.78 ARNT EPAS1 HIF1A VHL
10 11.69 ARNT CITED2 EGLN1 EGLN3 EP300 HIF1A
11
Show member pathways
11.6 ARNT EP300 HIF1A
12 11.55 HIF1A MTOR TIGAR
13 11.38 ARNT EP300 HIF1A
14 11.36 ARNT EGLN1 HIF1A HIF1AN
15 11.29 ARNT EGLN1 EGLN2 EP300 HIF1A HIF1AN
16
Show member pathways
11.26 ARNT CITED2 EGLN3 EP300 EPAS1 HIF1A
17 10.9 ARNT HIF1A HIF1AN HIF3A VHL
18 10.81 EPAS1 VHL
19 10.81 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
20 10.52 HIF1A HIF1AN

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.86 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 transcription factor complex GO:0005667 9.56 ARNT EP300 EPAS1 HIF1A
3 nucleoplasm GO:0005654 9.53 ARNT CITED2 EGLN2 EGLN3 EP300 EPAS1
4 RNA polymerase II transcription factor complex GO:0090575 9.33 ARNT HIF1A HIPK2

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.92 EPAS1 HIF1A HIF3A PSMA7 VHL
2 angiogenesis GO:0001525 9.88 EPAS1 HIF1A HIF3A RORA
3 positive regulation of endothelial cell proliferation GO:0001938 9.74 ARNT HIF1A MTOR
4 cellular response to hypoxia GO:0071456 9.7 EPAS1 HIF1A HIPK2 HYOU1 MTOR RORA
5 positive regulation of vascular endothelial growth factor production GO:0010575 9.65 ARNT HIF1A RORA
6 positive regulation of glycolytic process GO:0045821 9.62 ARNT HIF1A
7 mRNA transcription from RNA polymerase II promoter GO:0042789 9.62 ARNT HIF1A
8 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 ARNT HIF1A
9 response to hypoxia GO:0001666 9.61 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
10 iris morphogenesis GO:0061072 9.58 HIF1A HIPK2
11 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 ARNT EPAS1 HIF1A
12 oxygen homeostasis GO:0032364 9.54 EGLN1 HIF1A
13 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.54 EGLN1 EGLN2 EGLN3
14 voluntary musculoskeletal movement GO:0050882 9.51 HIPK2 MTOR
15 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.5 CITED2 HIF1AN VHL
16 positive regulation of hormone biosynthetic process GO:0046886 9.49 ARNT HIF1A
17 embryonic placenta development GO:0001892 9.43 ARNT EPAS1 HIF1A
18 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.4 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
19 embryonic camera-type eye morphogenesis GO:0048596 9.29 HIPK2
20 transcription, DNA-templated GO:0006351 10.26 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
21 regulation of transcription, DNA-templated GO:0006355 10.25 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
22 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.09 ARNT CITED2 EGLN1 EP300 EPAS1 HIF1A
23 oxidation-reduction process GO:0055114 10.03 EGLN1 EGLN2 EGLN3 HIF1AN HIGD1A P4HTM
24 negative regulation of apoptotic process GO:0043066 10 CITED2 HIF1A HIGD1A HYOU1 VHL
25 positive regulation of transcription, DNA-templated GO:0045893 10 ARNT CITED2 EP300 HIF1A HIPK2 RORA

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.91 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
2 transcription factor binding GO:0008134 9.85 ARNT EP300 EPAS1 HIF1A RORA VHL
3 protein dimerization activity GO:0046983 9.8 ARNT EPAS1 HIF1A HIF3A
4 iron ion binding GO:0005506 9.72 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 EGLN1 EGLN2 EGLN3 P4HTM
6 histone acetyltransferase binding GO:0035035 9.61 CITED2 EPAS1 HIF1A
7 dioxygenase activity GO:0051213 9.55 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
8 RNA polymerase II activating transcription factor binding GO:0001102 9.48 EP300 HIPK2
9 oxygen sensor activity GO:0019826 9.46 EGLN2 HIF1AN
10 peptidyl-proline 4-dioxygenase activity GO:0031545 9.43 EGLN1 EGLN2 EGLN3
11 L-ascorbic acid binding GO:0031418 9.26 EGLN1 EGLN2 EGLN3 P4HTM
12 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....